A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer

Lorenzo Fornaro, G. Masi, S. Bursi, F. Loupakis, E. Vasile, A. Antonuzzo, S. Chiara, E. Pfanner, A. Di Paolo, G. Bocci, M. Del Tacca, A. Falcone

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy than FOLFIRI in metastatic colorectal cancer patients. The aim of this study was to determine the maximum tolerated dose of capecitabine, in substitution of 5-fluorouracil, combined with oxaliplatin and irinotecan and to evaluate the pharmacokinetics of the drugs. Patients and methods: We treated 15 patients with escalating doses of capecitabine (from day 1 to 7) and fixed doses of oxaliplatin (85 mg/m2) plus irinotecan (165 mg/m2) (both administered on day 1), repeated every 2 weeks. Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment. Results: The maximum tolerated dose of capecitabine resulted 2,000 mg/m 2/day, with diarrhea being the only dose-limiting toxicity. Large interpatient variability in the pharmacokinetic parameters of investigated drugs was observed. Results in terms of activity are promising. Conclusions: At the maximum tolerated dose of capecitabine of 2,000 mg/m2/day the combination is feasible with promising activity and deserves further investigations.

Original languageEnglish
Pages (from-to)965-969
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume63
Issue number5
DOIs
Publication statusPublished - Apr 2009

Keywords

  • Capecitabine
  • Dose finding
  • Irinotecan
  • Metastatic colorectal cancer
  • Oxaliplatin
  • Triplet regimen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Fingerprint Dive into the research topics of 'A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this